Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Isonipecotic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.94 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.94 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.94 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.94 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.94 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.94 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.94 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.94 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.94 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.94 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.94 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.94 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.94 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.94 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.94 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.94 |
| ▸ | SLC6A1 known ✓ | P30531 | 2/20 | 0.50 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.94 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isonipecotic Acid SCHEMBL2560208 | 1.00 | TSHR (0.94) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Isonipecotic Acid SCHEMBL31602943 | 1.00 | TSHR (0.94) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Isonipecotic Acid SCHEMBL104297 | 0.97 | — | — | |
| Isonipecotic Acid SCHEMBL2027408 | 0.97 | TSHR (1.00) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Isonipecotic Acid SCHEMBL23043998 | 0.94 | TSHR (0.94) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Isonipecotic Acid SCHEMBL5035880 | 0.94 | TSHR (0.94) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Isonipecotic Acid SCHEMBL6122239 | 0.94 | TSHR (0.94) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Isonipecotic Acid SCHEMBL30060745 | 0.94 | TSHR (0.94) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Isonipecotic Acid SCHEMBL11556866 | 0.94 | TSHR (0.94) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Isonipecotic Acid SCHEMBL28089924 | 0.94 | TSHR (0.94) | TSHRGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116601149-A | Aminoquinazoline derivatives as P2X3 inhibitors | 奇斯药制品公司 | 2023-08-15 | — | — | CN | claimed |
| CN-115322143-B | Preparation method of 4-tert-butyl piperidine formate hydrochloride | 安徽德诺医药股份有限公司 | 2023-07-14 | — | — | CN | claimed |
| CN-115322143-A | Preparation method of 4-piperidine formic acid tert-butyl ester hydrochloride | 安徽德诺医药股份有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-108707151-A | Pyrimido-pyridazinone compound and application thereof | 阿萨纳生物科技有限责任公司 | 2018-10-26 | — | — | CN | claimed |
| CN-108601785-A | Purposes of the pyrimido pyridazinone in treating cancer | 阿沙纳生物科学公司 | 2018-09-28 | — | — | CN | claimed |
| CN-103974955-B | Pyrimido-pyridazinone compounds and uses thereof | 阿萨纳生物科技有限责任公司 | 2018-06-19 | — | — | CN | claimed |
| CN-103974955-A | Pyrimido-pyridazinone compounds and uses thereof | ENDO PHARMACEUTICALS INC | 2014-08-06 | — | — | CN | claimed |
| US-12383548-B2 | Antibacterial quinolines | Tecnimede—Sociedade Técnico-Medicinal, SA (PT) | 2025-08-12 | — | — | US | disclosed |
| US-20240336601-A1 | 4-PHENYL-INDOLE DERIVATIVES AND RELATED USES | CHULALONG UNIVERSITY (TH) | 2024-10-10 | — | — | US | disclosed |
| US-20240228461-A1 | NOVEL METHOD FOR PREPARING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | LG CHEM, LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
| CN-117222632-A | Crystalline forms of sphingosine-1-phosphate receptor agonists | 株式会社LG化学 | 2023-12-12 | — | — | CN | disclosed |
| CN-114728917-B | Oxamide derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117202893-A | Directly compressible pharmaceutical compositions comprising sphingosine-1-phosphate receptor agonists | 株式会社LG化学 | 2023-12-08 | — | — | CN | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| CN-1742013-A | Pyrazolopyrimidine compound and method for producing the same | TANABE SEIYAKU CO (JP) | 2006-03-01 | — | — | CN | disclosed |
| WO-2006020719-A2 | AMINOACID CONJUGATES OF BETA - LAPACHONE FOR TUMOR TARGETING | ARQULE, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| CN-1723210-A | Fused furan compound | TANABE SEIYAKU CO (JP) | 2006-01-18 | — | — | CN | disclosed |
| CN-1483031-A | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | ���ĵ�˹ҩ��ɷ�����˾ | 2004-03-17 | — | — | CN | disclosed |
| CN-1279669-A | Aromatic sulfone hydroxamic acid metalloprotease inhibitors | SEARLE & CO (US) | 2001-01-10 | — | — | CN | disclosed |
| EP-0208235-B1 | N-ARALKYL PIPERIDINEMETHANOL DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383548-B2 | Antibacterial quinolines | NQO2, RABGGTB, NQO1 | GABRP 2825/4885GABRD 2160/4885GABRA1 3643/4885 |
| US-20240336601-A1 | 4-PHENYL-INDOLE DERIVATIVES AND RELATED USES | PDCD1, PDCD1LG2, CD274 | GABRP 560/4885GABRD 2760/4885GABRA1 2384/4885 |
| US-20240228461-A1 | NOVEL METHOD FOR PREPARING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | S1PR1, S1PR2, S1PR5 | GABRP 323/4885GABRD 1094/4885GABRA1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.